Advancements in Targeted Quantitation of PFAS

Session #1 - Advancements in Targeted Quantitation of PFAS
We are thrilled to invite you to our upcoming webinar focused on enhancing laboratory efficiency and accuracy in PFAS analysis. Join us to explore innovative solutions that streamline processes and improve detection capabilities.
1. Harnessing the Power of Mass Spectrometry and Automation to Reduce Sample Size, Sample Preparation Time and Increase Laboratory Efficiency of PFAS Analysis for EPA 1633
- Presented by Kari Organtini
EPA Method 1633 is widely used for analyzing PFAS in non-potable water, soils, biosolids, and tissues. This presentation will show how advanced mass spectrometry and automation can significantly reduce sample size, cut down preparation time, and boost overall laboratory efficiency.
2. Identification of short chain per and polyfluorinated alkyl substances (PFAS) using ion ratios with low mass product ions
- Presented by Stuart Adams
As long-chain PFAS are replaced by short and ultrashort-chain alternatives, their detection becomes more challenging. This talk will cover how modified tandem quadrupole mass spectrometry enhances sensitivity, enabling the identification of these difficult-to-detect PFAS compounds using low-mass product ions.
3. Evaluation of DESI mounted on Q-TOF and TQ mass spectrometers to image PFAS compounds in different matrices
- Presented by Emmanuelle Claude
Direct analysis with minimum sample preparation as well spatial dimension of PFAS in samples can add simplicity and localization information, to complement state of the art detection and quantification by UHPLC-MRM analysis. Results are presented to evaluate the level of detection of few tens of PFAS compounds that were spotted on porcine liver tissue section, after updating the DESI imaging workflow to minimize external contamination. Several mass spectrometers such as discovery workflow in full scan TOF mode on the MRT and Cyclic mass spectrometers as well as targeted workflow using MRM acquisition mode on the DESI XS Xevo TQ Absolute MS were compared. Finally the benefit of ion mobility separation for the MSI analysis of PFAS is described. 61% and 55% of the PFAS compounds were detected as low as 10 ng/mL spotted on tissue when analyzed by negative mode DESI in discovery full scan MS acquisition mode. The targeted MRM workflow is the most sensitive system with 77% of the PFAS compounds detected as low as 10 ng/mL spotted on tissue.
Join us to learn how these technologies are transforming PFAS analysis, helping laboratories meet the growing demand for more efficient and accurate testing.
Presenter: Dr. Stuart Adams (Principal Scientist, Market Development, Food and Environmental Applications, Europe, Waters Corporation)
Stuart has been developing methods for the determination of contaminants in food and the environment for over 17 years and has been with Waters Corporation since 2018. Stuart's previous role was as a senior analytical chemist at Fera (the UK’s National Reference Laboratory) and moved to Waters to focus on application development in the European region. He now serves as the attached scientist to the European Market Development team responsible for the food and environmental application areas. In his role, he works with customers to understand their analytical challenges and helps address them with Waters technologies.
Presenter: Kari Organtini, Ph.D. (Principal Scientist, Food & Environmental, Waters Corporation)Kari Organtini is a senior scientist at Waters
Corporation and has been with the company for five years. She received her PhD from Penn State University in 2015 studying the occurrence of dioxins and furans in fire debris and their implications to first responder health. At Waters, Kari is part of the food and environmental applications team. Kari has developed applications using both LC and GC techniques for a variety of applications ranging from pesticides to persistent organic pollutants during her career. She is currently the scientific lead for developing PFAS applications at Waters.
Presenter: Emanuelle Claude (Consulting Scientist D&C Imaging, Waters Corporation)
Miss Emmanuelle Claude (Master in Fine Chemistry and Business and M.Phil in spectroscopy analysis in organic chemistry and biology) is currently a Consulting scientist in the Scientific Operations Department, Wilmslow, UK.She started at Waters Corporation in October 2000 as an Application Chemist in the Proteomics and Genomics Marketing group, developing automated Peptide Mass Fingerprint (PMF) MS methods using a MALDI-TOF mass spectrometer.
Over the years she developed several methods in the proteomics analytical space using MALDI TOF and naturally moved in starting the development of Mass Spectrometry Imaging (MSI) at Waters corporation over 15 years ago.
She has been involved with hardware and software R&D to ensure that the solutions are fit-for-purpose for the MSI community and beyond. She has worked extensively with the main MSI leaders in Europe and the US such as Prof Heeren in the Netherlands, Prof Clench, Prof Takats and Bunch in the UK and Prof Caprioli in the US. She has been a Principal Scientist since 2014 and became a Consulting scientist in 2021 and is part of the MS imaging application team at Waters where data are generated for collaborations and marketing activities (i.e. application literature, customer presentation, papers, posters...), hardware and software requirements are defined for the R&D teams. The team evaluates and develops new applications & methods for imaging by both MALDI and DESI mass spectrometry, support sales with customers visit and demonstration laboratory worldwide.
Presenter: Ken Rosnack (Principal Market Development Manager, Waters Corporation)
Ken Rosnack is a Principal Market Development Manager in the Testing & Lab Services Group for Waters Corporation. His primary focus is within regulated and routine LC-MS/MS environmental market where he is responsible for world-wide strategy implementation and performance. He maintains collaborations within regulatory agencies as well as with global industrial partners. Over his career, Ken has been primary author on numerous publications, been an invited speaker multi-nationally, and has presented at many conferences. He has been involved with MS for the past 40 years.
